RPWA
ALXN

Regent Peak Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Regent Peak Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-243
Closed -$38K – 1137
2020
Q4 		$38K Buy
+243
New +$31.2K 0.01% 345

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Regent Peak Wealth Advisors's ALXN Position: Q1 2021 in Review

Regent Peak Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 243 shares — an estimated $38K sold.

Regent Peak Wealth Advisors first reported a position in ALXN in Q4 2020 and held it in 1 quarter. The position peaked at $38K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Regent Peak Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Regent Peak Wealth Advisors sold 243 Alexion Pharmaceuticals shares in Q1 2021, an estimated $38K.
  • Regent Peak Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Regent Peak Wealth Advisors's Alexion Pharmaceuticals position peaked at $38K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Regent Peak Wealth Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.